NeOnc Technologies to Participate at the BTIG Virtual Biotechnology Conference

Company Overview - NeOnc Technologies Holdings, Inc. is a clinical-stage biotechnology company focused on developing treatments for brain and central nervous system cancers [2] - The company utilizes the NEO™ drug development platform, which has produced a portfolio of novel drug candidates and delivery methods, with patent protections extending to 2038 [2] - NeOnc's proprietary chemotherapy agents have shown positive effects in laboratory tests and clinical trials, particularly for malignant gliomas [2] Current Developments - NeOnc's therapeutics, NEO100™ and NEO212™, are currently in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status [2] - The company has an exclusive worldwide patent portfolio licensed from the University of Southern California, covering multiple uses for NEO100, NEO212, and other products [2] Upcoming Events - Management will participate in the BTIG Virtual Biotechnology Conference on July 29-30, 2025, providing an opportunity for investors to schedule one-on-one meetings [1]